Provided by Tiger Trade Technology Pte. Ltd.

Crinetics Pharmaceuticals Inc.

36.98
-0.3700-0.99%
Post-market: 37.300.3200+0.87%19:19 EDT
Volume:837.91K
Turnover:30.73M
Market Cap:3.87B
PE:-7.47
High:37.50
Open:37.38
Low:36.24
Close:37.35
52wk High:57.99
52wk Low:24.10
Shares:104.71M
Float Shares:96.32M
Volume Ratio:0.71
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.9500
EPS(LYR):-4.9500
ROE:-40.17%
ROA:-25.22%
PB:3.90
PE(LYR):-7.47

Loading ...

Mar 04, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 04, 2026

Major Issues Report

Form 8-K - Current report
Mar 02, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 26, 2026

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Feb 26, 2026

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 26, 2026

Major Issues Report

Form 8-K - Current report
Feb 02, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 26, 2026

Major Issues Report

Form 8-K - Current report
Jan 13, 2026

Major Issues Report

Form 8-K - Current report
Jan 07, 2026

Major Issues Report

Form 8-K - Current report
Jan 05, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 05, 2026

Major Issues Report

Form 8-K - Current report
Jan 02, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 17, 2025

Major Issues Report

Form 8-K - Current report
Dec 01, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 07, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 07, 2025

Major Issues Report

Form 8-K - Current report
Nov 03, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 02, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 26, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities